Rebimastat

DB06573InvestigationalSmall molecule

Investigated for use/treatment in lung cancer and prostate cancer.

Mechanism: Pharmacologically active on Matrix metalloproteinase-9, 72 kDa type IV collagenase, and Collagenase 3
Curator reviewed
Primary indication: Investigated for use/treatment in lung cancer and prostate cancer.Curator reviewed
Formula / weight: C₂₃H₄₁N₅O₅S · 499.67 g/mol (avg)
Code names: BMS-275291 · BMS 275291-01 · D-2163

Resolves to

Compound

Structure

InChIKeyGTXSRFUZSLTDFX-HRCADAONSA-NSMILESCNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C

Targets

What you can answer from here — as of June 15, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

21+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rebimastat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.